# SADAL (NCT02227251)

> Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

No report yet. It can be ordered.

- Drugs tested: selinexor
- Indication: relapsed/refractory diffuse large B-cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02227251
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Karyopharm Therapeutics Inc
- Conditions: Diffuse Large B-cell Lymphoma
- Interventions: Selinexor; Selinexor; Selinexor
- Enrollment: 244
- Primary outcome: Part 1: Overall Response Rate (ORR)
- Primary outcome: Part 2: Overall Response Rate (ORR) Based on Lugano Criteria

## Indexed commentary on SADAL so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sadal-nct02227251